METiS Therapeutics
METiS Therapeutics builds AI-enabled platforms to discover and deliver targeted therapeutics for serious diseases. The company combines artificial intelligence, machine learning, molecular dynamics simulations and high-throughput in vivo screening to design and optimize lipid nanoparticles (LNPs) and delivery systems for small molecules, RNA and gene therapies. METiS pursues collaborations and licensing with biopharmaceutical companies to advance candidate formulations. Its core technology stack centers on predictive AI models and MD-driven simulation coupled with experimental screening to validate delivery efficiency and safety. The company targets the therapeutic delivery market with scalable nanoparticle platforms aimed at multi-organ targeting and commercial partnerships.
METiS Therapeutics
METiS Therapeutics builds AI-enabled platforms to discover and deliver targeted therapeutics for serious diseases. The company combines artificial intelligence, machine learning, molecular dynamics simulations and high-throughput in vivo screening to design and optimize lipid nanoparticles (LNPs) and delivery systems for small molecules, RNA and gene therapies. METiS pursues collaborations and licensing with biopharmaceutical companies to advance candidate formulations. Its core technology stack centers on predictive AI models and MD-driven simulation coupled with experimental screening to validate delivery efficiency and safety. The company targets the therapeutic delivery market with scalable nanoparticle platforms aimed at multi-organ targeting and commercial partnerships.
TL;DR
What they do: AI-driven discovery and targeted delivery platforms (LNPs) for small molecules, RNA and gene therapies
Headquarters: Cambridge, Massachusetts
Founding year: 2017
Recent funding milestone: Series B announced Apr 5, 2022
Approx. team size: 31 employees
Company Overview
Problem Domain
Therapeutic delivery and drug discovery for small molecules, biologics and nucleic acids
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
Series B announced Apr 5, 2022
Series A announced Dec 7, 2021 (listed in public profiles)
Investor Signal
“Investors include PICC Capital Investment Management, China Life/China Life Private Equity, 5Y Capital, Lightspeed China Partners (Luminous Ventures), Monolith Management, CMB International, Frees Fund, HSG”